[go: up one dir, main page]

SI1226110T1 - Bicyclic amino acids as pharmaceutical agents - Google Patents

Bicyclic amino acids as pharmaceutical agents

Info

Publication number
SI1226110T1
SI1226110T1 SI200030670T SI200030670T SI1226110T1 SI 1226110 T1 SI1226110 T1 SI 1226110T1 SI 200030670 T SI200030670 T SI 200030670T SI 200030670 T SI200030670 T SI 200030670T SI 1226110 T1 SI1226110 T1 SI 1226110T1
Authority
SI
Slovenia
Prior art keywords
amino acids
pharmaceutical agents
bicyclic amino
bicyclic
pharmaceutical
Prior art date
Application number
SI200030670T
Other languages
English (en)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Residence Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SI1226110T1 publication Critical patent/SI1226110T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
SI200030670T 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents SI1226110T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
PCT/US2000/028687 WO2001028978A1 (fr) 1999-10-20 2000-10-17 Acides amines bicycliques utilises comme agents pharmaceutiques
EP00972226A EP1226110B1 (fr) 1999-10-20 2000-10-17 Acides amines bicycliques utilises comme agents pharmaceutiques

Publications (1)

Publication Number Publication Date
SI1226110T1 true SI1226110T1 (en) 2005-08-31

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030670T SI1226110T1 (en) 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents

Country Status (50)

Country Link
US (2) US6689906B1 (fr)
EP (2) EP1506955B1 (fr)
JP (2) JP3632191B2 (fr)
KR (2) KR100593349B1 (fr)
CN (1) CN1165518C (fr)
AP (2) AP2002002517A0 (fr)
AR (2) AR026087A1 (fr)
AT (2) ATE293590T1 (fr)
AU (2) AU778871B2 (fr)
BG (2) BG106719A (fr)
BR (1) BR0014972B1 (fr)
CA (1) CA2386297C (fr)
CO (1) CO5280060A1 (fr)
CR (1) CR6620A (fr)
CU (1) CU23112A3 (fr)
CZ (1) CZ295960B6 (fr)
DE (2) DE60019628T2 (fr)
DO (1) DOP2000000083A (fr)
DZ (1) DZ3197A1 (fr)
EA (1) EA005206B1 (fr)
EC (1) ECSP045393A (fr)
EE (1) EE200200211A (fr)
ES (2) ES2282785T3 (fr)
GE (1) GEP20043297B (fr)
GT (2) GT200000183AA (fr)
HK (1) HK1049826B (fr)
HN (1) HN2000000224A (fr)
HR (2) HRP20040709A2 (fr)
HU (1) HUP0203325A3 (fr)
IL (3) IL149143A0 (fr)
IS (2) IS6348A (fr)
MA (1) MA26842A1 (fr)
MX (1) MXPA02003229A (fr)
MY (1) MY127678A (fr)
NO (2) NO20021780D0 (fr)
NZ (1) NZ517961A (fr)
OA (1) OA12070A (fr)
PA (1) PA8505201A1 (fr)
PE (1) PE20010740A1 (fr)
PL (1) PL354607A1 (fr)
PT (1) PT1226110E (fr)
SI (1) SI1226110T1 (fr)
SK (1) SK5232002A3 (fr)
SV (1) SV2001000188A (fr)
TR (2) TR200500221T2 (fr)
TW (2) TW200505824A (fr)
UA (1) UA72931C2 (fr)
WO (1) WO2001028978A1 (fr)
YU (2) YU29302A (fr)
ZA (1) ZA200202543B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
ATE390133T1 (de) * 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (fr) * 2001-01-26 2002-07-31 Warner-Lambert Company Utilisation d'acides aminés bicycliques pour la prevention et le traitement des douleurs viscérales ainsi que des maladies gastrointestinales
ATE460392T1 (de) 2001-04-19 2010-03-15 Warner Lambert Co Kondensierte bizyklische oder trizyklische aminosäuren
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PT1404324E (pt) * 2001-06-11 2008-03-05 Xenoport Inc Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
CA2474000A1 (fr) 2002-01-31 2003-08-07 Warner-Lambert Company Llc Ligands alpha 2 delta dans le traitement des acouphenes
WO2003070237A1 (fr) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinaisons d'un ligand alpha-2-delta avec un inhibiteur selectif de cyclooxygenase-2
WO2004002462A2 (fr) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Methode de traitement du trouble d'hyperactivite avec deficit de l'attention
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
JP2005539092A (ja) * 2002-08-15 2005-12-22 ファイザー・インク 縮合二環式または三環式アミノ酸の治療における使用
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
EP2172197A1 (fr) 2002-12-13 2010-04-07 Warner-Lambert Company LLC Derive de l'acide octanoique pour le traitement de la fibromyalgie et d'autres douleurs
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
JP4479974B2 (ja) 2007-09-28 2010-06-09 第一三共株式会社 二環性γ−アミノ酸誘導体
WO2010110361A1 (fr) 2009-03-26 2010-09-30 第一三共株式会社 Méthode de production d'un dérivé d'acide γ-aminé bicyclique
WO2012169474A1 (fr) 2011-06-08 2012-12-13 第一三共株式会社 Procédé pour produire un composé bicyclique via un sel d'iminium
CN103562170B (zh) 2011-06-08 2015-09-02 第一三共株式会社 经由克莱森重排制备双环化合物的方法
CA2859003C (fr) 2011-12-15 2016-11-01 Daiichi Sankyo Company, Limited Procede de dedoublement optique pour compose bicyclique faisant appel a un catalyseur asymetrique
WO2013154066A1 (fr) 2012-04-10 2013-10-17 第一三共株式会社 Procédé de résolution optique d'un composé bicyclique utilisant une enzyme
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (fr) 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
CU23048A3 (es) 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos

Also Published As

Publication number Publication date
KR20060013701A (ko) 2006-02-13
CR6620A (es) 2004-02-02
YU73004A (sh) 2005-11-28
HK1049826B (zh) 2005-02-25
CU23112A3 (es) 2006-02-27
AR045456A2 (es) 2005-10-26
AU1092001A (en) 2001-04-30
HRP20020428A2 (en) 2005-02-28
NO20043663L (no) 2002-04-16
SV2001000188A (es) 2001-09-07
ES2282785T3 (es) 2007-10-16
WO2001028978A1 (fr) 2001-04-26
JP2003512348A (ja) 2003-04-02
DE60019628T2 (de) 2006-01-19
CN1165518C (zh) 2004-09-08
UA72931C2 (uk) 2005-05-16
EA005206B1 (ru) 2004-12-30
US6835751B2 (en) 2004-12-28
TR200500221T2 (tr) 2005-03-21
HRP20040709A2 (en) 2004-12-31
AR026087A1 (es) 2002-12-26
EP1226110A1 (fr) 2002-07-31
MXPA02003229A (es) 2002-09-30
ECSP045393A (es) 2004-10-23
EP1506955B1 (fr) 2007-03-28
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
OA12070A (en) 2003-11-10
US6689906B1 (en) 2004-02-10
BG108860A (en) 2006-03-31
SK5232002A3 (en) 2003-07-01
EA200200293A1 (ru) 2002-10-31
IL149143A (en) 2007-02-11
KR100593349B1 (ko) 2006-06-26
EP1506955A1 (fr) 2005-02-16
TWI225855B (en) 2005-01-01
TR200201094T2 (tr) 2002-09-23
YU29302A (sh) 2005-06-10
AP2002002517A0 (en) 2002-06-30
ES2237464T3 (es) 2005-08-01
BR0014972A (pt) 2002-07-16
CZ295960B6 (cs) 2005-12-14
ATE358116T1 (de) 2007-04-15
AU778871B2 (en) 2004-12-23
HN2000000224A (es) 2001-04-11
IL149143A0 (en) 2002-11-10
HK1049826A1 (en) 2003-05-30
US20040152779A1 (en) 2004-08-05
CN1382118A (zh) 2002-11-27
KR100566462B1 (ko) 2006-03-31
CA2386297C (fr) 2010-02-09
HRP20020428B1 (en) 2006-02-28
DE60034157D1 (de) 2007-05-10
BG106719A (bg) 2003-02-28
IS7497A (is) 2004-10-08
EP1226110B1 (fr) 2005-04-20
JP3632191B2 (ja) 2005-03-23
NO20021780L (no) 2002-04-16
JP3744928B2 (ja) 2006-02-15
NO20021780D0 (no) 2002-04-16
MA26842A1 (fr) 2004-12-20
PL354607A1 (en) 2004-01-26
CA2386297A1 (fr) 2001-04-26
CZ20021310A3 (cs) 2003-05-14
DE60034157T2 (de) 2007-12-13
IS6348A (is) 2002-04-17
IL164060A0 (en) 2005-12-18
GT200000183AA (es) 2005-06-17
ZA200202543B (en) 2003-09-23
DOP2000000083A (es) 2002-03-30
AP2004003186A0 (en) 2004-12-31
HUP0203325A3 (en) 2003-12-29
TW200505824A (en) 2005-02-16
BR0014972B1 (pt) 2011-09-06
NZ517961A (en) 2002-12-20
AU2005201268A1 (en) 2005-04-21
CO5280060A1 (es) 2003-05-30
KR20020040900A (ko) 2002-05-30
HUP0203325A2 (hu) 2003-02-28
DZ3197A1 (fr) 2001-04-26
PA8505201A1 (es) 2002-08-29
EE200200211A (et) 2003-06-16
ATE293590T1 (de) 2005-05-15
JP2005036009A (ja) 2005-02-10
MY127678A (en) 2006-12-29
DE60019628D1 (de) 2005-05-25
PE20010740A1 (es) 2001-07-27
PT1226110E (pt) 2005-07-29

Similar Documents

Publication Publication Date Title
HRP20020428A2 (en) Bicyclic amino acids as pharmaceutical agents
HUP0100472A3 (en) Novel amines as pharmaceutical agents
HUP0203506A3 (en) Modified peptides as therapeutic agents
PL351387A1 (en) Pharmaceutical composition
SI0964856T1 (en) Bicyclic amino acids
EG23937A (en) Novel pharmaceutical
GB9909041D0 (en) Novel pharmaceutical
GB9909075D0 (en) Novel pharmaceutical
GB9909154D0 (en) Pharmaceutical formulation
GB9926251D0 (en) Pharmaceutical formulation
GB9923934D0 (en) Novel pharmaceutical
HU0402095D0 (en) Bicyclic amino acids as pharmaceutically active ingredients
HUP9902307A3 (en) Novel bridged cyclic amino acids as pharmaceutical agents
SI0888325T1 (en) Novel cyclic amino acids as pharmaceutical agents
GB9930700D0 (en) Pharmaceutical formulation
GB9930878D0 (en) Pharmaceutical formulation
GB9917777D0 (en) Pharmaceutical formulation
GB9917775D0 (en) Pharmaceutical formulation
GB9917774D0 (en) Pharmaceutical formulation
GB9917772D0 (en) Pharmaceutical formulation
GB9921396D0 (en) Pharmaceutical formulation
GB9927685D0 (en) Pharmaceutical formulation
GB9919840D0 (en) Pharmaceutical formulation
GB9910636D0 (en) Pharmaceutical formulation
GB9910633D0 (en) Pharmaceutical formulation